Open label and single cohort study of edaravon on Muro disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex :Kii ALS/PDC)

Open label and single cohort study of edaravon on Muro disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex :Kii ALS/PDC) - Edaravon on Muro disease (Kii ALS/PDC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006103

Enrollment

Registered

2011-08-20

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muro disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex : Kii : ALS/PDC)

Interventions

Edaravon, 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who live or have lived in ALS/PDC focus of Mie prefecture. 2) ALS: probable ALS diagnosed by El Escorial criteria. PDC: patients with dementia and parkinsonism. 3) Range of Age: 20 y.o -80 y.o. 4) Requirement a caregiver of patient. 5) Patients who can take a medical examination at Minami Ise Hospital regularly. 6) Informed consent.

Exclusion criteria

Exclusion criteria: 1) A patient with other neuronal or muscular disorders 2) A patients with systemic disorders those present dementia, parkinsonism or amyotrophy 3) Encephalitis 4) A patients with abnormal neuroradiological findings those suggest other disorders present dementia, parkinsonism or amyotrophy 5) A patients with severe psychiatric disorders 6) A patient with malignancy 7) A patient with severe renal dysfunction 8) A patient wit sever heart dysfunction 9) A patient with severe liver dysfunction 10) A patient with sever drug allergy 11) A patients with drug or alcoholic abuse 12) A patient with pregnancy or in the lactation period 13) A patient who was inappropriate for this study

Design outcomes

Primary

Measure	Time frame
CAS/CAT,motivation score in Japan	—

Secondary

Measure	Time frame
1. ALSFRS-R, 2.UPDRS, 3. MMSE, 4. FAB	—

Countries

Japan

Contacts

Public ContactJunko Karita

Mie University, Graduate School of Regional Innovation Studies Kii ALS/PDC Research Center

kii-project@clin.medic.mie-u.ac.jp+81-59-231-5117

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026